Der Einsatz von Amisulprid bei Patienten mit Morbus Huntington

Zusammenfassung

Hintergrund: Das Benzamidderivat Amisulprid wird als Neuroleptikum der zweiten Generation mit günstigem Nebenwirkungsprofil beschrieben. Methodik: Wir berichten über vier Patienten mit Morbus Huntington und Zeichen einer Psychose, die mit Amisulprid behandelt wurden. Ergebnisse: Zwei Patienten entwickelten Zeichen eines medikamentös induzierten extrapyramidal-motorischen Syndroms, in allen Fällen war die antipsychotische Therapie erfolgreich. Diskussion: Aufgrund des zunehmenden Untergangs striataler Neurone treten bei Patienten mit M. Huntington auch unter Amisulprid bereits früh extrapyramidal-motorische Nebenwirkungen auf.

Abstract

Objectives: Amisulpride is a substituted benzamide derivative with atypical antipsychotic properties and low side effects. Method: We report four cases of patients with clinically and genetically established Huntington's disease and signs of psychosis who were treated with Amisulpride. Results: Two patients developed extrapyramidal side effects due to the treatment. The antipsychotic therapy of all patients was effective. Discussion: Due to degeneration of striatal neurons patients suffering from Huntington's disease react early with development of extrapyramidal side effects after therapy with amisulpride.

Literatur

• 1 Gusella J F, Wexler N S, Conneally P M, Naylor S L, Anderson M A, Tanzi R E, Watkins P C, Ottina K, Wallace M R, Sakaguchi A Y. et al . A polymorphic DNA marker genetically linked to Huntington's disease.  Nature. 1983;  306 (5940) 234-238
• 2 Weindl A, Conrad B. Chorea und choreatische Bewegungsstörungen. In: Conrad B, Ceballos-Baumann AO (Hrsg) Bewegungsstörungen in der Neurologie. Stuttgart, New York; Thieme 1996: 155-180
• 3 Kanzig S, Eichorn M. Psychotic syndrome in chorea Huntington.  Psychiatr Prax. 2003;  30 (5) 286-287
• 4 Schoenfield M, Myers R H. Increased rate of suicide among patients with Huntington's disease.  J Neurol Neurosurg Psychiat. 1984;  47 1283
• 5 Berardelli A, Noth J, Thompson P D, Bollen E L, Curra A, Deuschl G, Dijk J G van, Topper R, Schwarz M, Roos R A. Pathophysiology of chorea and bradykinesia in Huntington's disease. Review.  Mov Disord. 1999;  14 (3) 398-403
• 6 Anderson K E, Marder K S. An overview of psychiatric symptoms in Huntington's disease. Review.  Curr Psychiatry Rep. 2001;  3 (5) 379-388
• 7 Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, Oblin A, Gonon F, Carter C, Benavides J, Scatton B. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.  J Pharmacol Exp Ther. 1997;  280 (1) 83-97
• 8 Delcker A, Schoon M L, Oczkowski B, Gaertner H J. Amisulpride versus haloperidol in treatment of schizophrenic patients-results of a double-blind study.  Pharmacopsychiatry. 1990;  23 (3) 125-301
• 9 Moller H J, Boyer P, Fleurot O, Rein W. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group.  Psychopharmacology (Berl). 1997;  132 (4) 396-401
• 10 Wetzel H, Grunder G, Hillert A, Philipp M, Gattaz W F, Sauer H, Adler G, Schroder J, Rein W, Benkert O. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology - a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group.  Psychopharmacology (Berl). 1998;  137 (3) 223-232
• 11 Peuskens J, Bech P, Moller H J, Bale R, Fleurot O, Rein W. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group.  Psychiatry Res. 1999;  88 (2) 107-117
• 12 Danion J M, Rein W, Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group.  Am J Psychiatry. 1999;  156 (4) 610-616
• 13 Colonna L, Saleem P, Dondey-Nouvel L, Rein W. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group.  Int Clin Psychopharmacol. 2000;  15 (1) 13-22
• 14 Leucht S, Pitschel-Walz G, Engel R R, Kissling W. Amisulpride, an unusual „atypical” antipsychotic: a meta-analysis of randomized controlled trials.  Am J Psychiatry. 2002;  159 (2) 180-190
• 15 Coulouvrat C, Dondey-Nouvel L. Safety of amisulpride (Solian): a review of 11 clinical studies.  Int Clin Psychopharmacol. 1999;  14 (4) 209-218
• 16 Schotte A, Janssen P F, Gommeren W, Luyten W H, Gompel P van, Lesage A S, Loore K de, Leysen J E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.  Psychopharmacology (Berl). 1996;  124 (1 - 2) 57-73
• 17 Rein W, Coulouvrat C, Dondey-Nouvel L. Safety profile of amisulpride in short- and long-term use.  Acta Psychiatr Scand Suppl. 2000;  400 23-27
• 18 Briken P, Nika E, Krausz M, Naber D. Atypical neuroleptics in the treatment of aggression and hostility in schizophrenic patients.  Fortschr Neurol Psychiatr. 2002;  70 (3) 139-144
• 19 Tarsy D, Baldessarini R J, Tarazi F. Effects of newer antipsychotics on extrapyramidal function.  CNS Drugs. 2002;  16 (1) 23-45
• 20 Green B. Focus on amisulpride.  Curr Med Res Opin. 2002;  18 (3) 113-117
• 21 Saleem P, Olie J P, Loo H. Social functioning and quality of life in the schizophrenic patient: advantages of amisulpride.  Int Clin Psychopharmacol. 2002;  17 (1) 1-8